Is there a disparity in medications for opioid use disorder based on race/ethnicity and gender? A systematic review and meta-analysis
Background Access to medications for opioid use disorder (MOUD) among racial/ethnic
minorities is a growing concern. Objectives Inequalities in receiving MOUD among gender …
minorities is a growing concern. Objectives Inequalities in receiving MOUD among gender …
Improving research on racial disparities in access to medications to treat opioid use disorders
TL Mark, AG La Sonya, G McMurtrie… - Journal of addiction …, 2023 - journals.lww.com
Objectives The aims of the study are to review the current research on the association
between access to medications for opioid use disorders (MOUD) and race, to identify gaps …
between access to medications for opioid use disorders (MOUD) and race, to identify gaps …
'Red flags' and 'red tape': telehealth and pharmacy-level barriers to buprenorphine in the United States
L Textor, D Ventricelli, SV Aronowitz - International Journal of Drug Policy, 2022 - Elsevier
Background Structural vulnerabilities for people who use drugs (PWUD) were exacerbated
by the COVID-19 pandemic. In this context, federal lawmakers in the United States (US) …
by the COVID-19 pandemic. In this context, federal lawmakers in the United States (US) …
Intersectional stigma as a fundamental cause of health disparities: A case study of how drug use stigma intersecting with racism and xenophobia creates health …
Recent evidence points to racial and ethnic disparities in drug-related deaths and health
conditions. Informed by stigma, intersectionality, intersectional stigma, and fundamental …
conditions. Informed by stigma, intersectionality, intersectional stigma, and fundamental …
Racial health disparities in the United States
Abstract Disparities between Black and White Americans in health care coverage and health
outcomes are pervasive in the United States. In this paper, we describe the evolution of the …
outcomes are pervasive in the United States. In this paper, we describe the evolution of the …
Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the …
Background Community stigma toward people with opioid use disorder (OUD) can impede
access to harm reduction services and treatment with medications for opioid use disorder …
access to harm reduction services and treatment with medications for opioid use disorder …
The medications for opioid use disorder study: methods and initial outcomes from an 18-month study of patients in treatment for opioid use disorder
JA Dever, MF Hertz, LJ Dunlap… - Public Health …, 2024 - journals.sagepub.com
Objective: Opioid use disorder (OUD) affects approximately 5.6 million people in the United
States annually, yet rates of the use of effective medication for OUD (MOUD) treatment are …
States annually, yet rates of the use of effective medication for OUD (MOUD) treatment are …
Variation in intervention stigma among medications for opioid use disorder
Despite a substantial evidence base for effectiveness, medications for opioid use disorder
(MOUD) are often stigmatized. Even healthcare professionals working in substance use …
(MOUD) are often stigmatized. Even healthcare professionals working in substance use …
Drug overdose mortality by race/ethnicity across US-born and immigrant populations
Background The present study examined racial/ethnic differences in US drug overdose
mortality among US-born and foreign-born men and women. Methods In this cross-sectional …
mortality among US-born and foreign-born men and women. Methods In this cross-sectional …
Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic
Importance COVID-19 disrupted delivery of buprenorphine and naltrexone treatment for
opioid use disorder (OUD), and during the pandemic, members of racial and ethnic minority …
opioid use disorder (OUD), and during the pandemic, members of racial and ethnic minority …